杜鲁特格拉维尔
阿巴卡韦
拉米夫定
中止
养生
医学
内科学
不利影响
背景(考古学)
耐受性
胃肠病学
药理学
病毒载量
病毒学
人类免疫缺陷病毒(HIV)
抗逆转录病毒疗法
病毒
乙型肝炎病毒
古生物学
生物
作者
Gianmaria Baldin,Arturo Ciccullo,Stefano Rusconi,Giordano Madeddu,Gaetana Sterrantino,Andrew Freedman,Andrea Giacometti,Luigi Celani,Alessandra Latini,Barbara Rossetti,Maria Vittoria Cossu,Andrea Giacomelli,Filippo Lagi,Amedeo Capetti,Simona Di Giambenedetto
出处
期刊:PubMed
日期:2019-12-01
卷期号:27 (4): 410-414
被引量:1
摘要
We investigated the effectiveness and safety of a dual therapy (DT) with lamivudine plus dolutegravir versus a single tablet regimen (STR) with abacavir/lamivudine/dolutegravir. We performed a retrospective analysis in a cohort of virologically suppressed HIV+ patients switching to lamivudine-dolutegravir or abacavir/lamivudine/dolutegravir. We evaluated the incidence of virological failure and treatment discontinuation, as well as their predictors. Non-parametric tests were applied to assess changes in immunological and metabolic parameters. In all, 616 patients were analyzed: 380 began STR and 236 DT. In the STR group three patients experienced VF; in the DT group seven patients experienced VF. No differences in cause of treatment discontinuation were found. The estimated probability of continuing therapy at 48 weeks were 88.5 % in DT and 90.3% in STR, without a statistically significant difference (Log-rank 0.338). Regarding the metabolic profile, in the STR group there was a reduction in LDL cholesterol levels at week 48 (p=0.008), whereas in the lamivudine group there was a significant reduction in total cholesterol level at week 48 (p=0.044). Regarding the renal function, in both groups we registered a reduction in estimated glomerular filtration rate (eGFR), with a median reduction of 8.4 ml/min in the STR group (p<0.001) and 10.2 mL/min in DT (p<0.001). We found a difference in strategy option: in a context of side effect and comorbidities, dual therapy strategy was preferred. Conversely, simplification and compliance improvement more frequently translated into a DTG-STR strategy.
科研通智能强力驱动
Strongly Powered by AbleSci AI